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Abstract
Dilated cardiomyopathy (DCM) is a genetic
or acquired heart muscle disorder character-
ized by dilation and impaired contraction of
one or both ventricles. In the acquired forms of
the disease, if the pathogenic agent is persist-
ent, undiagnosed or untreated, permanent
ultrastructural and morphological changes
may lead to irreversible dysfunction.
Conversely, when DCM is promptly recognized
and treated, the heart may show an extraordi-
nary ability to recover from left ventricular
(LV) systolic dysfunction. While much
research in heart failure has focused on mor-
bidity and mortality associated with persistent
LV systolic dysfunction, relatively little atten-
tion has been devoted to this remarkable
potential for recovery. In this two-part review
we will focus on the most common types of
reversible DCM. The second part will deal with
chemotherapy-induced cardiomyopathy, alco-
hol-related cardiomyopathy, myocarditis and
peripartum cardiomyopathy. Although diverse
in etiopathogenesis, genetic background, ther-
apeutic options and outcome, the forms of
DCM characterized by reversible LV dysfunc-
tion share similar challenges in diagnosis and
clinical management. The identification of
pathways to recovery may show the way for
novel therapeutic targets ultimately benefit-
ting all cardiac patients.
Chemotherapy-induced cardiomyopathy
Chemotherapy is a well-known cause of car-
diomyopathy (Table 1) and the cardiac toxic
effects of anthracyclines, prototypal in cardio-
oncology, have been investigated for more than
30 years.1 Although acute cardiotoxicity is pos-
sible, chronic cardiotoxicity is more common;
its occurrence and severity are proportional to
the cumulative dose (for example doxorubicin
>400-500 mg/m2 is associated with significant
risk) and may become evident several years
after exposure. Occasionally, the gap may be
sufficiently long as to render the association
between chemotherapy and cardiomyopathy
counterintuitive. Serial echocardiographic
assessment of left ventricular (LV) systolic
function is commonly used to evaluate
chemotherapy-induced cardiomyopathy, while
cardiovascular magnetic resonance (CMR) is
indicated as a second-line investigation when
evident disease or borderline abnormalities
are identified.2 Historically, cardiotoxicity is
defined by a ≥5% decline in LV ejection frac-
tion (LVEF) resulting in an LVEF <55% with
symptoms of heart failure, or a 10% decline to
result in an LVEF <55% without symptoms of
heart failure,1,3 or ≥20% or >15% LVEF decline
from baseline, but remaining ≥50%, or any
LVEF decline to <50%.4 Clinical manifestations
vary from mild, subclinical systolic impairment
to severe dilated cardiomyopathy and refracto-
ry heart failure. Today, about half of the
patients surviving cancer die of cardiovascular
complications of treatment. There are 2 major
types of cardiotoxicity-type 1 and 2. Type 1
(typical caused by anthracyclines) is associat-
ed with ultrastructural changes, poor progno-
sis and lower recovery rates. Type 2 cardiotox-
icity (for example caused by trastuzumab), is
not associated with histological changes and
have better prognosis.5 Chemotherapy-induced
cardiomyopathy represents 2.5% of all heart
transplant recipients.6
Biomarkers such as troponin, natriuretic
peptides, C-reactive proteins and others have
been proposed as early markers of cardiotoxic-
ity and are useful in predicting risk. Treatment
is still empirical and mainly based on standard
heart failure medications. Recovery of LV sys-
tolic function has been reported up to 55% of
patients in 2 years.7 Prevention of chemother-
apy-induced cardiomyopathy involves careful
evaluation of the type and dose of oncologic
regimens and the use of dexrazoxane, an eth-
ylenediaminetetraacetic acid-like chelator that
reduces oxidative damage. In addition, preven-
tive therapy with b-blockers (carvedilol),
angiotensin-converting enzyme (ACE)-
inhibitors and statins may be effective,
although the evidence supporting their protec-
tive role is limited. A recent meta-analysis of a
small number of trials showed a relative risk
reduction in risk of heart failure or LVEF
decline following chemotherapy of approxi-
mately 70% for b-blockers and 90% for ACE-
inhibitors.8 These data support the concept
that optimization of hemodynamics and neuro-
hormonal milieu prior to anthracycline therapy
may help to prevent myocyte injury. Another
promising strategy for the management of LV
dysfunction due to anticancer treatment relies
on the use of novel, more sensitive diagnostic
techniques allowing earlier recognition of
myocardial damage. Most relevantly, strain
echocardiography and cardiac MRI, along with
biomarkers such as cardiac troponins and NT-
proBNP have shown the best results in terms
of risk assessment for the timing of early inter-
ventions.1,2,4
To date, the pathogenesis of cardiotoxicity
associated with anthracycline therapy is still
poorly understood. The most commonly accept-
ed hypothesis for anthracycline-induced car-
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diomyopathy has been the generation of exces-
sive amount of reactive oxygen species (ROS)
by electron exchange between the anthracy-
cline quinone and oxygen molecules and/or
other intracellular molecular targets.9 Other
mechanisms include the formation of DNA
adducts by anthracyclines emiquinone or the
generation of superoxide anions by anthracy-
cline metabolism, with subsequent cellular
damage caused by superoxide anions with sub-
sequent degradation of sarcomeric proteins,
mitochondrial dysfunction and DNA damage.10
Although in vivo and in vitro studies confirmed
increased ROS production in cardiomyocytes
after anthracycline therapy, antioxidants and
iron chelation only showed partial positive
effects and none of them was able to prevent
cardiomyopathy.11,12 Topoisomerase (Top) 2b
was recently revealed as the main determinant
of anthracycline-induced cardiac toxicity.13 The
physiological role of Top2 is to unfold DNA
strands during DNA replication, transcription,
or recombination.14 Anthracy cline-induced pro-
duction of oxygen radicals appears to be mainly
due to a reduction in antioxidant enzyme gene
transcription, which is also Top2b-dependent.13
Top2b-inhibition also leads to impaired mito-
chondrial bioge nesis and function. Indeed, dele-
tion of Top2b gene from the heart fully protects
mice from anthracycline-induced cardiomyopa-
thy, supporting the idea that Top2b is the pri-
mary mediator of anthracycline-induced car-
diotoxicity.
Recent studies also postulated an additional
mechanism for chemotherapy-induced car-
diotoxicity, which is related with the dysfunc-
tion of resident myocardial stem cells.
Historically, cardiomyocytes have been consid-
ered as terminally differentiated cells, with no
postnatal turnover. However, several recent
studies15-18 provided strong evidence of the
presence of a cardiomyocyte turnover in the
human heart controlled by a resident stem cell
population. Cardiac cell turnover has been
recently quantified by measuring the amount
of carbon 14 (14C) integrated into DNA of car-
diomyocytes from subjects born both before
and after the nuclear bomb tests.16 By fitting
those measurements with an appropriate
mathematical model, the calculated annual
rate of cardiomyocyte renewal was 1% at 25
years of age and decreased to 0.45% at 75.16
Higher values are observed in non-cardiomy-
ocytes myocardial cells (e.g., fibroblasts). In
the normal human heart nearly 14 myocytes
per million of cells are actually dividing.15 More
than 150 cardiomyocytes per million of cells
are subject to apoptosis.19 Therefore, if a small
fraction of cardiac myocytes is cycling, it may
be sensitive to the antiproliferative action of
anthracyclines. Proliferating myocytes
increase in the damaged human heart (e.g.,
after ischemia).15 The same phenomenon may
be active in anthracycline-induced cardiomy-
opathy and repeated administrations of the
drug will gradually reduce the population of
myocyte progenitors that are activated to
repair the damage, resulting in a time-depen-
dent accumulation of cardiac injury. The high
incidence of late cardiotoxicity in the pediatric
oncology population may well be explained by
the deleterious effects of anthracyclines on the
higher fraction of proliferating cardiomyocytes
typical of young hearts.20 Indeed, a higher
turnover leads to an increased susceptibility to
cytotoxic insult and progressive cells death in
young cancer survivors. Stem cells hold the
great promise of regenerative therapies such
as those used for myocardial infarction.21
Recent results on rats have shown that dys-
function of cardiac stem cells occurs early after
drug exposure and that doxorubicin-induced
cardiomyopathy can be prevented by injection
of cardiac stem cell.22
Finally, other agents such as cisplatin, 5-flu-
orouracil and rituximab may cause myocardial
damage mediated by ischemia, whether
through coronary artery spasm or endothelial
impairment. Ischemia can occur in patients
without underlying coronary artery disease
(CAD), but the incidence is higher in patients
with CAD.23
Alcohol-related cardiomyopathy
Daily consumption of low to moderate
amounts of alcohol has been shown to have
potent beneficial effects on the cardiovascular
system.24,25 In contrast, it is known since late
19th century that chronic exposure to high lev-
els of alcohol for a long period could lead to
progressive cardiac dysfunction and heart fail-
ure.24,25 Excessive alcohol intake is currently
recognized as a common cause of dilated car-
diomyopathy (DCM), and DCM due to alcohol
abuse is known as alcohol-related cardiomy-
opathy (ACM) (Table 1, Figure 1).25,26 The evi-
dence supporting excessive alcohol exposure
as a cause of DCM includes several experi-
mental studies,25 epidemiological studies
showing higher prevalence of excessive alco-
hol consumption in DCM patients than in the
general population,27 and echocardiographic
studies in asymptomatic alcohol abusers.28
Based on experimental studies the patho-
physiology of ACM includes several processes
with a crucial role of apoptosis29 and excess
oxidative stress.30 In addition, genetic predis-
position is likely to play a major role.25,31
Individual susceptibility to ACM is supported
by the fact that only a small subset of alcohol
abusers develop the disease. Prevalence of
ACM in DCM series range from 23 to 47% mak-
ing ACM the leading cause of DCM in western
countries.25 The diagnosis of ACM is usually
one of exclusion in a patient with DCM with no
identified cause and a long history of heavy
alcohol abuse. 
Data on the amount of alcohol consumption
required to cause ACM are limited and contro-
versial in that a proportional relationship
between myocardial damage and alcohol
intake has not been proven. In most studies on
the natural history and the long-term progno-
sis of ACM, an amount of 80 g a day (equiva-
lent to 10 U or 5 glasses of 12% wine or 3-4
pints of beer) during at least 5 years was
deemed sufficient to produce the disease.32-35
However, average alcohol consumption shown
by the patients included in these series was
much higher and consumption periods were
much longer. Furthermore, the accepted defi-
nition of ACM does not take into account
important factors such as body mass index
(BMI) or sex. For example, women and indi-
viduals with lower BMI are significantly more
susceptible to the negative effects of alcohol.
A recent study examined the contemporary
natural history of ACM.36 In this study involv-
ing 94 patients evaluated at a single referral
center during the period 1994-2011, approxi-
mately one third died or needed a heart trans-
plant while another third showed persistent LV
dysfunction despite lack of adverse events. The
final third progressively normalized their car-
diac function. In this study predictors of poor
outcome (death and heart transplant) were
absence of b-blocker treatment, atrial fibrilla-
tion and QRS>120 ms.36
Recommended treatment in ACM does not
differ from other forms of DCM and should
include guideline-based anti-failure medica-
tions.25 Special attention should be paid to b-
blocker treatment given its protective effect in
the above mentioned study.36 Although there
are no specific randomized studies examining
the efficacy of implatable cardioverter defibril-
lators (ICDs) on ACM, a device should always
be considered in patients with ACM and
severely impaired systolic function, who seem
to be at higher risk of malignant ventricular
arrhythmias compared to other DCM
patients.37,38 On the other hand, the ultimate
decision regarding an ICD is challenging,
because LVEF can greatly improve in the first
year after diagnosis. Only one study has specif-
ically investigated the incidence of ventricular
arrhythmias in ACM.38 Investigators reported
that no malignant ventricular arrhythmias
were found among ACM patients if LVEF had
improved to or remained ≥40%.38
Complete withdrawal is recommended to all
patients with ACM and may lead to complete
recovery of cardiac function, and three long-
term studies have shown better outcomes of
ACM in abstainers than in patients who main-
tained alcohol consumption.32-34 Nevertheless,
there is controversy regarding the need for
complete alcohol withdrawal in ACM. The con-
troversy emerges from the observation that
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studies evaluating the effect of alcohol absti-
nence included patients who reduced alcohol
intake to low/moderate levels alongside with
those who stopped consuming alcohol com-
pletely.21-34 Furthermore, the only contemporary
study found that prognosis and degree of LVEF
recovery in ACM patients who decreased alco-
hol intake to moderate levels was comparably
favorable to that of abstainers.36 Ultimately,
complete alcohol cessation appears desirable
for ACM patients giving the fact that these
patients have suffered an important addiction
and may find it extremely difficult to maintain
low-moderate intakes over time.
Basic research studies have described sev-
eral mechanisms that could be involved in
determining the functional and structural
alterations found in ACM, linked both to
ethanol and its main metabolite, acetaldehyde.
Most studies highlight abnormalities of intra-
cellular organelles causing alterations in the
energetic metabolism and calcium homeosta-
sis, which are especially relevant for the devel-
opment of contractile anomalies. The mecha-
nisms described to date include: apoptosis,39
up-regulation of the L-type calcium channels,40
alterations of the excitation-contraction cou-
pling in cardiac myocytes,41 structural and
functional alterations of the mitochondria and
sarcoplasmic reticulum,42 changes in calcium
sensitivity of myofilaments,43 alterations of
mitochondrial oxidation,39 deregulation of pro-
tein synthesis, decrease of contractile pro-
teins44 and activation of the renin-angiotensin
system and of the sympathetic nervous
system.45 To date, however, the sequence of
events that occur in alcohol-induced myocar-
dial damage are unresolved.
Myocarditis
Myocarditis (Table 1) is an inflammatory
disease of the heart muscle and is defined
immunohistochemically by the presence on
endomyocardial biopsy of ≥14 leucocytes/mm2-
including up to 4 monocytes/mm2- with the
presence of CD3 positive T-lymphocytes ≥7
cells/mm2.46 Myocarditis can be suspected clin-
ically in symptomatic subjects [chest pain,
pseudoischemic electrocardiographic (ECG)
pattern, dyspnea, unexplained arrhythmias,
cardiogenic shock] in the presence of one or
                             Review
Table 2. Reversible dilated cardiomyopathies.
Disease                   Diagnosis                    Etiology                            Prevalence              Recovery              Prognosis                      Specific therapy
Chemotherapy-                A ≥5% decline LVEF             -   ROS generation                       3-26% of                             Up 55% in                     -  Poor for type                         -    Reduce dose/
induced CMP                    resulting in an LVEF            -   Formation of DNA adducts   patients undergoing        2 years7                           I cardiotoxicity: 60%                 discontinuation of the 
                                            <55% with symptoms          -   Top2β inhibition                     chemotherapy1                                                            mortality at 2-3                          chemotherapic agent 
                                            of heart failure, or a            -   Dysfunction of resident                                                                                               years for doxorubicin,       -    Earlier detection 
                                            ≥10% decline to result            myocardial stem cells                                                                                                   up to 40% for                              of myocardial  damage
                                            in an LVEF <55%                  -   Ischemia (cisplatin,                                                                                                      cyclophosphamide                   (strain echocardiography, 
                                            without symptoms                    5-fluorouracil                                                                                                               -  Low mortality for type              CMR, proBNP, etc.)
                                            of heart failure1,3                        and rituximab)1-5                                                                                                             II cardiotoxicity:5                         -    Dexrazoxane (debated)
                                                                                                                                                                                                                                               2.5% of all heart                   -    b-blockers, 
                                                                                                                                                                                                                                               transplant6                                                 ACE-inhibitors
                                                                                                                                                                                                                                                                                                    and statins (debated)
                                                                                                                                                                                                                                                                                                 -    Stem cell therapy 
                                                                                                                                                                                                                                                                                                      (experimental)
Alcohol-related CMP       Dilatation and                        80 g a day of                                   Up to 40% of                     37% at 4 years                At 4 years from                   -    Complete alcohol
                                            impaired                                 alcohol intake                              DCM pts in                        from                                 diagnosis,                                withdrawal
                                            contraction                            (equivalent                                   western                             diagnosis36                       30% dies or                         -    Standard anti-failure 
                                            of the left ventricle              To 10 U or 5                                   countries36                                                                   needs a heart                          medications, 
                                            or both ventricles                glasses of 12%                                                                                                                     transplant, 33%                       with special priority 
                                            related to excessive            wine or 3-4 pints                                                                                                                 shows persistent                   to β-blockers
                                            alcohol intake                        of beer) for at                                                                                                                     LV dysfunction36 
                                                                                               least 5 years
Myocarditis                     Inflammatory                      -   Viral infections                     9-16% of DCM                - 50%                           At 11 years follow                 Antiviral agents 
                                          disease of the                         (PVB19, HHV6,                      adult patients46                 non-fulminant        up 93% of fulminant            (interferon),
                                          heart muscle                           enterovirus,                                                                        acute                       myocarditis pts alive            immunosuppression
                                          on EMB:                                    adenovirus,                                                                       myocarditis46           compared to 45%                  (azathioprine, cortisone), 
                                          ≥14 leucocytes/mm2-            influenza A virus,                                                            - Up to 90% of           of acute                                  immunomodulation
                                          including up to 4                    EBV, CMV,                                                                           fulminant                myocarditis pts57                   (intravenous 
                                          monocytes/mm2-                    HCV, HIV)                                                                            myocarditis56                                                           immunoglobulin) 
                                          with the presence             -   Other infectious                                                                                                                                                    (debated and 
                                          of CD3 positive                       agents (bacterial,                                                                                                                                                  controversial)
                                          T-lymphocytes                         fungal, protozoal)
                                          ≥7 cells/mm2 46                             -   Immuno-mediated 
                                                                                                                                              toxic agents
Peri-partum CMP          LVEF <45% or FS               -   Viral myocarditis                  1:4000 to                          Up to 65%                  - If dilation and                     -   Avoid all teratogenic
                                          <30% or both58                   -  Auto-immunity                      1:1000                               of patients                    systolic dysfunction             drugs if pregnancy/
                                          presenting                           -  Inflammation                         live births                        within 6 months           persist, the prognosis          lactation is ongoing, 
                                          with signs                            -  Increased oxidative            in the Western               of delivery62                            is poor                                      including 
                                          of cardiac                                 stress and apoptosis           World60,61                                                                                               -  If there is full                         ACE-inhibitors 
                                          failure during                     -   Malnutrition                                                                                                             recovery within                       and ARBs
                                          the last month                    -   Prolactin                                                                                                                    6 months from                   -   Bromocriptine (debated)
                                          of pregnancy or                  -   Hemodynamic stress                                                                                            delivery, the prognosis     -   Pentoxifylline 
                                          within 5 months                 -   Genetic milieu                                                                                                        is excellent                             (debated)
                                          of delivery26                              (Titin gene)65 
CMP, cardiomyopathy; LVEF, left ventricular ejection fraction; ROS, reactive oxidative species; CMR, cardiovascular magnetic resonance; ACE-inhibitors, angiotensin-converting enzyme inhibitors; DCM, dilated cardiomyopathy; EMB, endomy-
ocardial biopsy; PVB19, parvovirus B19; HHV6, human herpesvirus 6; EBV, Epstein-Barr virus; CMV, citomegalovirus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; FS, fractional shortening; ARBs, angiotensin II receptor blockers.
No
 co
mm
erc
ial
 us
e o
nly
                                             [Cardiogenetics 2016; 6:5862]                                                               [page 11]
more diagnostic criteria: ECG and/or Holter
monitoring abnormalities (brady- and tach-
yarrhythmias), elevated cardiac enzymes,
functional and structural abnormalities detect-
ed by cardiac imaging including tissue abnor-
malities detected by CMR. The diagnosis can
also be suspected in asymptomatic subjects
when two or more diagnostic criteria from dif-
ferent categories are met. Estimated incidence
is 22/100,000/year.47 Viral infections [par-
vovirus B19 (PVB19), human herpesvirus 6,
enterovirus, adenovirus, influenza A virus,
Epstein-Barr virus, citomegalovirus, hepatitis
C virus, human immunodeficiency virus] are
the most common cause of myocarditis, fol-
lowed by other infectious agents (bacterial,
fungal, protozoal, etc.), immuno-mediated
causes and toxic agents. Using polymerase
chain reaction technology, viral RNA or DNA is
commonly identified within the myocardium of
affected patients.48 Extensive studies per-
formed in biopsy and autopsy myocardial spec-
imens have linked specific viral infections
with up to 69% of cases of clinical myocardi-
tis.49 Moreover, elevated serum levels of anti-
bodies against specific viruses have been
detected in patients with idiopathic dilated
cardiomyopathy.50
Little is known about the early stages of
acute viral myocarditis in patients.
Enteroviruses (e.g., Coxsackie-B viruses) are
responsible for one quarter of cases49 and their
mechanism of damage to the myocardium has
been well characterized in animal models.
Enteroviruses gain access to the host via the
gastrointestinal or respiratory tracts, the heart
being a secondary target. Myocardial infection
occurs in 3 subsequent phases: i) viral entry
into cardiomyocytes and activation of innate
immunity; ii) viral replication and activation of
acquired immune responses; iii) resolution
with recovery or development of chronic dilat-
ed cardiomyopathy. Initial viral entry is medi-
ated by a specific cell-surface receptor.
Enteroviruses and adenoviruses recognize a
common transmembrane receptor on car-
diomyocytes, the coxsackievirus and aden-
ovirus receptor.51,52 This is essential for the ini-
tiation of the infection53 and subsequent viral
replication leading to myocyte necrosis.54
Natural killer cells, macrophages, and T lym-
phocytes migrate towards the infection site,
causing additional myocardial injury. The lat-
ter starts the second phase, where autoim-
mune reactions activate T cells that target host
myocardium. High levels of cytokines are liber-
ated during which can further potentiate car-
diomyocyte damage and reduce contractile
function. Phase 2 (the subacute phase) can
last weeks to months; in most patients, ven-
tricular contractile function improve as the
amount of replicating viruses diminishes.
However, the cardiomyopathy may enter a
chronic phase, which becomes irreversible.
Other viruses cause myocarditis by different
mechanisms. PVB19 can hibernate after a pri-
mary infection in childhood and later infect
the cardiac endothelium. PVB19 genomes have
been found in cardiac endothelial cells in
patients with fulminant myocarditis.55 Though
not directly infecting cardiomyocytes, the virus
exerts its pathogenic effects by local activation
of cytokines [tumor necrosis factor a (TNF-a)
and interleukin-6 (IL-6)] and induction of
endothelial apoptosis. Endothelial damage may
in turn compromise tissue perfusion, causing
myocardial ischemia. Moreover, accumulation
of lymphocytes in the coronary microcircula-
tion leads to a sustained rise in coronary
resistance, contributing to myocyte necrosis. 
Although myocarditis is an acquired dis-
ease, genetic polymorphisms may facilitate
viral infection and direct cellular damage and
may play a role in subsequent immuno-mediat-
ed injury. In addition, genetically determined
DCM may represent a preferential substrate
for myocarditis. Clinical presentation may be:
i) fulminant (lymphocytic, giant cell myocardi-
tis), which can rapidly evolve towards cardio-
genic shock and death, but may resolve com-
pletely in survivors; ii) acute, which often
resolves completely; and iii) chronic active
myocarditis, characterized by ongoing inflam-
mation and damage leading to DCM. 
Complete recovery of LV function occurs in
about 50% of patients with non-fulminant
acute myocarditis46 and up to 90% of patients
with fulminant myocarditis.56 In one study, at
11 years follow up 93% of fulminant myocardi-
tis patients were alive compared to 45% of
patients with acute myocarditis.57 Supportive
and standard anti-failure medications are still
the cornerstone of treatment. The evidence
favoring specific therapy with antiviral agents
(for example interferon), immunosuppression
(azathioprine, cortisone), immunomodulation
(intravenous immunoglobulin) is still based
on small studies46 and controversial. It is
unclear why some patients have full recovery
and others have persistent LV dysfunction. In
addition, it is not clear how long heart failure
treatment is needed after normalization of LV
function. Finally, it is still controversial
whether family screening should be consid-
ered, as evidence of myocardits does not
exclude genetically determined DCM or - in
patients presenting with sudden cardiac death
- a channellopathy. 
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Figure 1. Echo still frame images (diastole top panels, systole bottom panels) from a 52-
year old male admitted for acute heart failure and past medical history including hyper-
tension, atrial fibrillation and consumption of 100 g of alcohol per day for more than 20
years and normal coronary arteries. An echocardiogram (left panels) showed a very dilat-
ed left ventricle (LV), with LV ejection fraction <25% and right ventricular (RV) mild to
moderate systolic dysfunction. An echocardiogram performed 6 years after first evalua-
tion (right panels), after standard heart failure medication and complete alcohol intake
withdrawal, shows normal LV and RV size and function. 
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Peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCMP)
(Table 1) is an increasingly recognized entity
characterized by LV dysfunction (defined as LV
ejection fraction <45% or fractional shorten-
ing <30% or both58 presenting with signs of car-
diac failure during the last month of pregnancy
or within 5 months of delivery,26 where no
other cause of heart failure is found. LV func-
tion tends to recover in the majority of cases
within 6-12 months. Duration of standard anti-
failure medication after normalization of LV
function is unknown. The risk of PPCMP with
subsequent pregnancies, although still uncer-
tain, depends on recovery of LV function, and
has been described in up to 50% of patients
with persistent dysfunction compared to 20%
in patients with LVEF normalization.59 The
mechanism of relapse remains unclear and it
is unknown whether preventive measure can
be implemented in patients with prior history
of PPCMP undergoing a new pregnancy.
The prevalence of PPCMP has been estimat-
ed to be 1:4000 to 1:1000 live births in the
Western world.60,61 Advanced maternity age,
race (African), twin gestation, multiparity,
gestational hypertension, chronic hyperten-
sion, preeclampsia, prolonged use of tocolytics
are known risk factors for PPCMP.62 The etiolo-
gy remains largely unknown. Viral myocardits,
auto-immunity, inflammation, increased
oxidative stress and apoptosis, genetic predis-
position, malnutrition, prolactin and hemody-
namic stress have all been proposed as patho-
genetic or contributing mechanisms. Familial
occurrence of PPCMP has been described and
genetic association has been shown in mice
and humans.63,64 Recently, a large study on 172
PPCMP patients, showed a prevalence of trun-
cating variants (especially in the Titin gene)
similar to DCM patients, suggesting that these
variants may predispose to the condition.65
Myocarditis appears to be the main patho-
physiological mechanism in PPCMP. A 76%
incidence of myocarditis at myocardial biopsy
was reported in a study on a large number of
patients with PPCMP.66 Inflammatory cytokines
have also been named as possible leading
causative factors for PPCMP. In patients with
PPCMP, some studies found elevated plasma
levels of cytokines, such as TNF-a and IL-6, as
well as Fas/APO-1 (a apoptosis-signaling sur-
face receptor).67 Cytokines may lead to PPCMP
through initiation of an inflammatory cascade
when they come in contact with fetal cells that
have reached the maternal circulation during
delivery. These cells may have initially escaped
the maternal immune system because of the
immunosuppressive state of pregnancy. These
cells are therefore able to settle in various
organs, including cardiac tissue, leading to an
autoimmune trigger when the maternal
immune system effectiveness is restored
shortly after delivery.68 The hemodynamic
stress associated with pregnancy (increased
preload and decreased afterload) has been
shown to cause LV remodeling and hypertro-
phy.69 The physiological reduction in LV sys-
tolic function brought on by the reverse-
remodeling process after delivery may be more
exaggerated in subjects with peripartum car-
diomyopathy. Animal studies supported the
role of prolactin in peripartum cardiomyopa-
thy. Decreased levels of myocardial signal
transduction lead via catabolism of prolactin to
an antiangiogenic and proapoptotic isoform of
the hormone in the heart, which may cause
PPCMP.70 Of note, these results have been con-
firmed in patients, supporting a specific anti-
prolactin therapeutic strategy.
Recovery of LV systolic function has been
reported in up to 65% of patients within 6
months of delivery.62 Management of PPCMP
includes standard heart failure regimen, but
careful consideration must be made to avoid
all teratogenic drugs if the pregnancy is ongo-
ing, including angiotensin-converting enzyme
inhibitors and angiotensin-receptor blockers.
Hydralazine and nitrates may be safely used as
alternative therapies. b-adrenoceptor blockers
may also be used during pregnancy.
Immunosuppressive agents and immunoglob-
ulins may be considered in patients with biop-
sy-proven myocarditis that have not improved
after two weeks of standard heart failure ther-
apy.66,71 Bromocriptine, which inhibits pro-
lactin secretion, has been shown to promote
recovery of LV function in a small PPCMP
cohort,72 but safety issues have limited its use
in clinical practice.73 The anti-inflammatory
agent pentoxifylline has been investigated in a
small trial74 and shown to be effective, but fur-
ther evidence is required. 
Clinical perspective
The diverse forms of dilated cardiomyopathy
associated with a potential for recovery of LV
dysfunction share a number of features. The
etiology may be uncertain and a specific diag-
nosis may be often difficult. An history of
stressful events may lack in Tako-Tsubo car-
diomyopathy, the role of concomitant tach-
yarrhythmias may be unclear in tachycardia-
induced cardiomyopathy (TIC), patients may
have had chemotherapy in the past with dubi-
ous impact on later occurrence of LV dysfunc-
tion, the amount of alcohol consumption may
be difficult to ascertain and DCM found during
pregnancy may be pre-existing. Sometimes,
more than a possible cause is found, and all
these conditions may represent acquired dis-
ease sponsored by genetic predisposition or
unmask true genetic DCM, which should
prompt family screening. The molecular mech-
anisms underlying these conditions are often
unclear and it is still unknown how long heart
failure treatment needs to be continued once
LV function has recovered and whether pri-
mary or secondary prevention is possible, for
example before starting a potential cardio-
toxic chemotherapy or planning a new preg-
nancy. Specific treatments are emerging for
some conditions (e.g., peripartum cardiomy-
opathy or autoimmune myocarditis), but still
based on small studies. In all these forms, early
recognition appears a cornerstone for clinical
management, before permanent ultrastructur-
al and structural damage occur, in order to
improve likelihood of recovery. For example,
recognizing TIC is fundamental as LV dysfunc-
tion may be completely reversible once tachy-
cardia has been controlled, even though it may
have been so severe as to be considered for
transplantation.75 It is also important to note
that a significant minority of cases of dilated
cardiomyopathy recover even in absence of
reversible factors. Finally, these conditions
represent paradigms of cardiac recovery sug-
gesting a number of molecular mechanisms,
which might be exploited in other cardiac con-
ditions that are at present progressive and
unresponsive to therapy. The identification of
pathways to recovery also shows the way for
novel therapeutic targets ultimately benefit-
ting all cardiac patients. However, the road
ahead towards definite evidence and practical
application remains long and winding. 
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